- Conditions
- Appendicitis, Surgery
- Interventions
- Sugammadex, Neostigmine/Glycopyrrolate
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–38
of 38
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- CW 002
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Spine Surgery
- Interventions
- sugammadex, Neostigmine
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- SCI
- Interventions
- IN NEO, IN NEO + IN Glycopyrrolate, IV Visit
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Reversal of Neuromuscular Blockade
- Interventions
- Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more
- Conditions
- Postoperative Nausea and Vomiting, Respiratory Conditions Due to Other External Agents
- Interventions
- Sugammadex, Neostigmine
- Drug
- Lead sponsor
- Virtua Health, Inc.
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Mount Holly, New Jersey
- Conditions
- Burns
- Interventions
- Sugammadex, Neostigmine, Glycopyrrolate
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
- Interventions
- Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
- Drug · Device
- Lead sponsor
- James J. Peters Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Spinal Cord Injury, Neurogenic Bowel
- Interventions
- Neostigmine and Glycopyrrolate
- Drug
- Lead sponsor
- James J. Peters Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
- Interventions
- Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
- Drug · Device
- Lead sponsor
- James J. Peters Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Bowel Dysfunction, Postoperative Complications, Neuromuscular Blockade
- Interventions
- Sugammadex, Neostigmine
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Neuromuscular Blockade
- Interventions
- Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 1 Day to 2 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more
- Conditions
- Surgery
- Interventions
- Neostigmine+glycopyrrolate, Sugammadex
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 4
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
- Conditions
- Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
- Interventions
- Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts